Go to Health Care Provider version
| Diagnosis | Hodgkin Disease, Hodgkin lymphoma, relapsed, refractory | Study Status | Closed to enrollment |
| Phase | II |
| Age | Child, Adult - (5 Years to 30 Years) | Randomisation | NO |
| Line of treatment | Disease relapse or progression |
| Routes of Treatment Administration | IV |
| Last Posted Update | 2023-01-05 |
| ClinicalTrials.gov # | NCT02927769 |
International Sponsor
Bristol-Myers SquibbPrincipal Investigators for Canadian Sites
Montreal Children's Hospital – Dr. Sharon Abish
Alberta Children's Hospital – Dr. Victor Lewis
The Hospital for Sick Children - Dr. Ute BartelsCentres
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Medical contact
Dr. Victor Lewis
Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Study Description
The purpose of this study is to determine whether the combination of two drugs called nivolumab and brentuximab vedotin is safe and effective in treating patients with Hodgkin's lymphoma that has come back or not responded to current therapy.
Brentuximab vedotin is an antibody that specifically targets the CD30 marker of the Hodgkin Lymphoma cells and is able to kill them.
Nivolumab is a human monoclonal antibody that binds and blocks PD-1 on tumors cells. The PD-1 pathway is an immune system checkpoint that may be used by cancer tumour cells to help them trick the immune system (escape surveillance) and avoid being destroyed. By blocking the PD-1 pathway, nivolumab reactivates cells from the patient's immune system to help it identify and destroy the cancer cells. It is expected to slow or stop the growth of cancer cells.
Inclusion Criteria
Child aged 5 to 18 with Hodgkin lymphoma who has already received treatment and either had no response (refractory) or experienced relapse.
Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team.
